Experimental PF Therapy Granted U.S. Patent Allowance

Experimental PF Therapy Granted U.S. Patent Allowance

Galectin Therapeutics, Inc., announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application “Method for Treatment of Pulmonary Fibrosis” — number 13/999,389 — on its lead compound GR-MD-02. Galectin Therapeutics is currently developing carbohydrate-based therapies…

How to Treat Pulmonary Fibrosis

There is currently no cure for pulmonary fibrosis and patients often face a prognosis of three to five years after diagnosis. However, medication and other treatment options can help improve patients’ quality of life. Medication for the treatment of patient with pulmonary fibrosis Nintedanib…

7 Pulmonary Fibrosis Headlines You Can’t Miss

1. 6 Non-Pharmacological Pulmonary Fibrosis Treatments In this article, we’re focusing on bringing you non-pharmacological pulmonary fibrosis treatments. Check this list to discover 6 non-pharmacologic pulmonary fibrosis treatments. Read more about it: https://bit.ly/1SgrR74 2. Pulmonary Fibrosis: How Do Stem Cells…